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Abstract
The secoiridoids 3,4-dihydroxyphenylethanol-elenolic acid (3,4-DHPEA-EA) and 3,4-dihydroxyphenylethanol-elenolic acid dialdehyde
(3,4-DHPEA-EDA) account for approximately 55 % of the phenolic content of olive oil and may be partly responsible for its reported
human health benefits. We have investigated the absorption and metabolism of these secoiridoids in the upper gastrointestinal tract.
Both 3,4-DHPEA-EDA and 3,4-DHPEA-EA were relatively stable under gastric conditions, only undergoing limited hydrolysis. Both secoir-
idoids were transferred across a human cellular model of the small intestine (Caco-2 cells). However, no glucuronide conjugation was
observed for either secoiridoid during transfer, although some hydroxytyrosol and homovanillic alcohol were formed. As Caco-2 cells
are known to express only limited metabolic activity, we also investigated the absorption and metabolism of secoiridoids in isolated, per-
fused segments of the jejunum and ileum. Here, both secoiridoids underwent extensive metabolism, most notably a two-electron reduction
and glucuronidation during the transfer across both the ileum and jejunum. Unlike Caco-2 cells, the intact small-intestinal segments contain
NADPH-dependent aldo-keto reductases, which reduce the aldehyde carbonyl group of 3,4-DHPEA-EA and one of the two aldeydic car-
bonyl groups present on 3,4-DHPEA-EDA. These reduced forms are then glucuronidated and represent the major in vivo small-intestinal
metabolites of the secoiridoids. In agreement with the cell studies, perfusion of the jejunum and ileum also yielded hydroxytyrosol and
homovanillic alcohol and their respective glucuronides. We suggest that the reduced and glucuronidated forms represent novel physiologi-
cal metabolites of the secoiridoids that should be pursued in vivo and investigated for their biological activity.
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Metabolism
Adherence to the so-called Mediterranean diet(1) is believed to
provide protection against an array of common chronic patho-
logical conditions, including CHD, cancer and neurodegenera-
tive disorders(2–4). These effects may be mediated by many
individual components of the diet, including polyphenolic
phytochemicals present in various fruits and vegetables, red
wine and olive oil(4–6). With regard to olive oil, these polyphe-
nols include phenyl alcohols, such as hydroxytyrosol (HT),
tyrosol and secoiridoids, and phenyl alcohols conjugated to
elenolic acid. In particular, olive oil is a rich source of oleuro-
pein aglycone, 3,4-dihydroxyphenylethanol-elenolic acid
(3,4-DHPEA-EA, HT linked to elenolic acid) and a related
compound 3,4-dihydroxyphenylethanol-elenolic acid dialde-
hyde (3,4-DHPEA-EDA, HT linked to the dialdehydic form
of elenolic acid)(7) (Fig. 1). These compounds account for
up to 55 % of the total phenolic fraction(8–10), with 3,4-
DHPEA-EDA and 3,4-DHPEA-EA achieving a relatively high
concentration depending on growing conditions, cultivar
and storage conditions(9,10). These secoiridoid aglycones,
together with other phenolic components and tocopherols,
are believed to be partly responsible for the observed health
benefits of extra virgin olive oil consumption(5,6).
*Corresponding author: Dr J. P. E. Spencer, email j.p.e.spencer@rdg.ac.uk
Abbreviations: 3,4-DHPEA-EA, 3,4-dihydroxyphenylethanol-elenolic acid; 3,4-DHPEA-EAH2, methyl 4-(2-(3,4-dihydroxyphenethoxy)-2-oxoethyl)-3-
(hydroxymethyl)-2-methyl-3,4-dihydro-2H-pyran-5-carboxylate; 3,4-DHPEA-EDA, 3,4-dihydroxyphenylethanol-elenolic acid dialdehyde; 3,4-DHPEA-EDAH2,
2-(3,4-dihydroxyphenyl)ethyl (4E)-4-formyl-3-(2-hydroxyethyl)hex-4-enoate; AP, apical; BA, basolateral; ECACC, European Collection of Cell Culture; HT,
hydroxytyrosol; HVA, homovanillyl alcohol; LC, liquid chromatography; RT, retention time.
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In vitro studies have indicated that 3,4-DHPEA-EDA and
3,4-DHPEA-EA may protect erythrocytes(11,12) and mono-
nuclear cells(13) against oxidative injury. Furthermore, they
are known to reduce the viability of human breast carcinoma
cells(14) and induce apoptosis in mammary epithelial cells
overexpressing human epidermal growth factor receptor-
2(15) via the modulation of human epidermal growth factor
receptor-2 auto-phosphorylation(16). However, the biological
properties of 3,4-DHPEA-EDA and 3,4-DHPEA-EA in vivo
will depend on the extent to which they are absorbed and
metabolised in the gastrointestinal tract. Absorption studies
with olive oil, or phenolic extracts derived from olive oil,
have indicated that HT is absorbed(17–22), while other pheno-
lic components undergo metabolism in the small and large
intestine to yield homovanillic acid and homovanillyl alcohol
(HVA)(23–25). For example, oleuropein (3,4-DHPEA-EA gluco-
side) is not absorbed in the small intestine, but undergoes
rapid degradation in the large intestine to yield HT(23).
However, unlike oleuropein, it is thought that its correspond-
ing aglycone (3,4-DHPEA-EA) may be absorbed in the small
intestine due to its higher partition coefficient (log p)
value(26,27). As such, the aim of the present study was to inves-
tigate the absorption and metabolism of the secoiridoids
3,4-DPEA-EA and 3,4-DHPEA-EDA in the small intestine.
We focus on their decomposition in the stomach and their
absorption and metabolism in two small-intestinal models in
order to acquire knowledge relating to their fate in the gastro-
intestinal tract and the generation of metabolites that may
exert potential bioactivity in vivo.
Experimental methods
Materials
The aglycone 3,4-DHPEA-EA was obtained from oleuropein
via enzymatic cleavage using b-glycosidase (Fluka, Buchs,
Switzerland)(28), while 3,4-DHPEA-EDA was extracted from
olive leaves, as described previously(29). 3,4-DHPEA-EA that
was isolated following b-glycosidase treatment was found to
consist of a mixture of approximately 3·7:6·3 of its cis- and
trans-isomers. The purity of both compounds was assessed
by liquid chromatography (LC)–MS and 1H NMR and was
determined to be more than 95 % pure. HT was purchased
from Cayman Chemical Company (Ann Arbor, MI, USA).
HVA and b-glucuronidase (type L-II from limpets) were pur-
chased from Sigma (Poole, Dorset, UK). The Caco-2 cell line
was obtained from the European Collection of Cell Cultures
(ECACC) (Salisbury, Wiltshire, UK). Cell culture media and
supplements were obtained from PAA Laboratories (Yeovil,
Somerset, UK). HPLC-grade solvents were obtained from
Fisher (Hampton, NH, USA), and HPLC columns were
obtained from Waters (Watford, Herts, UK). All other reagents
used were obtained from Sigma.
Low pH conditions
3,4-DHPEA-EDA or 3,4-DHPEA-EA (1 mM) was incubated in
simulated gastric pH conditions (water and HCl; pH 2) at
378C for 1 and 4 h. As the aqueous system had no inherent
buffering capacity, we monitored pH throughout incubations
in order to assess whether compound hydrolysis influences
pH. However, there was no significant change in pH during
any of the incubations. Following incubation, samples were
analysed by HPLC-diode-array detection (see later).
Transport experiments using human Caco-2 cells
Caco-2 cells (passage 25–40) were grown in T-75 culture
flasks and passaged with a trypsin–versene solution. Cells
were cultured in Dulbecco’s modified Eagle’s medium sup-
plemented with fetal bovine serum (20 %, v/v), non-essential
amino acids (1 %, v/v), L-glutamine (2 mM), penicillin (100
units/ml) and streptomycin (100mg/ml) at 378C in 5 % CO2.
For all transcellular transport studies, Caco-2 cells were
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Fig. 1. Structures and amounts of olive oil secoiridoids under study obtained after the incubation of compounds at 378C, pH 2. (A) , 3,4-Dihydroxyphenylethanol-
elenolic acid dialdehyde (3,4-DHPEA-EDA); , hydroxytyrosol. (B) , 3,4-Dihydroxyphenylethanol-elenolic acid (3,4-DHPEA-EA); , hydroxytyrosol. Values are
means of at least four separate experiments, with standard errors represented by vertical bars. a,b,c Mean values with unlike letters were significantly different (P,0·05).
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seeded in 12 mm internal diameter transwell inserts (polycar-
bonate membrane, 0·4mm pore size; Corning Costar Corpor-
ation, Cambridge, MA, USA) in twelve-well plates at a
density of 5 £ 104 cells/ml. The basolateral (BA, serosal) and
apical (AP, mucosal) compartments contained 1·5 and 0·5 ml
of the culture medium, respectively. The culture medium
was replaced three times a week for 21 d. Before transport
experiments, the media in both chambers were replaced
with HEPES-buffered medium (pH 7·4; 5 mM-HEPES,
154 mM-NaCl, 4·6 mM-KCl, 33 mM-glucose, 5 mM-NaHCO3 and
1·2 mM-Na2HPO4). Only inserts with a transepithelial electrical
resistance value of .300V/cm2 were used for transport
experiments. 3,4-DHPEA-EA or 3,4-DHPEA-EDA (50, 100
and 200mM) was added in the AP side of transwells and incu-
bated for 2 h. Following incubation, the medium from both
compartments was harvested, snap-frozen and was analysed
by HPLC. Control experiments to monitor the oxidation and
hydrolysis of both compounds in medium alone (i.e. in the
absence of cells) were performed. In control experiments,
DHPEA-EA and 3,4-DHPEA-EDA were observed to undergo
only a very small level of spontaneous degradation to yield
HT (2 h, 378C; data not shown).
Transport and metabolism experiments in the perfused rat
intestinal model
Transport and metabolism experiments were conducted using
the in vitro intestinal preparation of Fisher & Gardner(30,31),
in which the lumen of the isolated intestine is perfused with
a segmental flow (perfusion of buffer interspersed with
the gas mixture) of bicarbonate buffer (pH 7·4) equilibrated
with 95 % O2:5 % CO2 and containing 28 mM-glucose. The
bicarbonate buffer consisted of 25 mM-HCO3
2, 143 mM-Naþ,
133·7 mM-Cl2, 5·9 mM-Kþ, 1·2 mM-HPO4
2, 2 mM-Ca2þ and
1·2 mM-Mg2þ. Male Sprague–Dawley rats (230–260 g) were
anaesthetised with sodium pentobarbital (90 mg/kg, intra-
peritoneally), and sections of the jejunum (20–30 cm long,
beginning 10 cm from the ligament of Treitz) or ileum
(20–30 cm long, ending 5 cm from the ileo-caecal junction)
were cannulated, and the lumen was segmentally perfused.
The intestinal sections were then removed from the animal
by stripping them from the mesentery, and suspended in a
chamber containing liquid paraffin (378C). Segmental flow
was maintained throughout this procedure. Before transport
experiments, the segments were perfused for 40 min in
order to flush blood from the vasculature and to allow fluid
absorption to reach a steady state. Thereafter, an aliquot of
the methanol stock solution of 3,4-DHPEA-EA or 3,4-
DHPEA-EDA was added to the carbonate buffer (final concen-
tration 100mM, methanol content 0·1 %) and perfused through
the intestinal segment, in a single-pass fashion, for up to
80 min. Appropriate vehicle controls, lacking polyphenols,
were also conducted. During perfusion, absorbed fluid
dropped through the paraffin to the base of the chamber
and was collected at timed intervals of 20 min. All samples
(pre-perfusion, post-perfusion and timed serosal fluids) were
snap-frozen and stored at 2208C until analysis. Serosal fluid
samples were analysed by HPLC and LC–MS both pre- and
post-b-glucuronidase treatment to establish the presence of
glucuronide conjugates. Aliquots of serosal fluid samples
(100ml) were added to 50ml of phosphate buffer (final con-
centration 0·1 M; pH 4·5) with or without the glucuronidase
enzyme (2000 units/ml), and samples were incubated for
120 min at 378C. The 0·1 M-phosphate buffer effectively inhibits
all sulphatase activity that the enzyme possesses. After incu-
bation, samples were centrifuged at 13 200 rpm for 10 min,
and aliquots of the supernatant were used for HPLC and
LC–MS analysis.
HPLC analysis
Characterisation and quantification of phenolic components
and metabolites in serosal samples and cell medium samples
were carried out using a Hewlett-Packard 1100 series liquid
chromatography system (Hewlett-Packard, Palo Alto, CA,
USA) equipped with a diode array detector (HP ChemStation
Software system). Samples were analysed by reverse-phase
HPLC using a Nova-Pak C18 column (4·6 £ 250 mm2) with
4mm particle size. The temperature of the column was main-
tained at 308C. The mobile phases consisted of a mixture of
aqueous methanol (5 %) in 0·1 % 5M-HCl (A) and a mixture
of aqueous acetonitrile (50 %) in 0·1 % 5M-HCl (B) and were
pumped through the column at 0·7 ml/min. The following gra-
dient system was used (min/% B): 0/5, 5/5, 40/50, 55/100,
59·9/100, 60/5, with 10 min post-run for both compound and
metabolite detections. The eluent was monitored by photo-
diode array detection at 280 nm, and spectra of products
were obtained over the 200–600 nm range. Calibration
curves of the compounds (0·1–100mM) were constructed
using authentic standards (HT, HVA, 3,4-DHPEA-EA and
3,4-DHPEA-EDA), and in each case, they were found to be
linear with correlation coefficients higher than 0·992. Quantifi-
cation of glucuronides (i.e. following b-glucuronidase
treatment) and reduced derivatives of 3,4-DHPEA-EA and
3,4-DHPEA-EDA was achieved using 3,4-DHPEA-EA and
3,4-DHPEA as standards.
Liquid chromatography–mass spectrometry analysis
Metabolite characterisation was achieved using LC–MS/MS uti-
lising electrospray ionisation. This consisted of an Agilent 1200
HPLC system equipped with a binary pump, degasser, auto-
sampler, thermostat, column heater, photodiode array detector
and an Agilent 1100 Series LC/MSD mass trap spectrometer.
Separation of samples was achieved using a Zorbax SB C18
column (2·1 £ 100 mm2; 1·8mm; Agilent, Santa Clara, CA,
USA), and HPLC conditions were as follows: injection
volume, 1ml; column temperature, 258C; binary mobile
system: (A) 0·1 % of aqueous formic acid and (B) 0·1 % of
formic acid in acetonitrile; flow rate, 0·2 ml/min. A series of
linear gradients was used for separation (min/%B): 0/10,
3/10, 15/40, 40/70, 50/70 and 65/10. MS was performed in
the negative ion mode (scan range, m/z 100–800 Da; source
temperature, 3508C). All solvents used were of LC–MS grade.
Metabolism of olive oil secoiridoids 1609
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Statistical analysis
Statistical analyses were performed using SPSS 18 statistical
software (SPSS, Inc., Chicago, IL, USA). Results are reported
as means with their standard errors of at least three separated
experiments. Data were analysed by one-way ANOVA fol-
lowed by the Tukey–Duncan a post hoc test, and differences
were considered significant at P,0·05. The Pearson corre-
lation coefficient (R) was used to indicate the strength of a
linear relationship. A P value lower than 0·05 was considered
as evidence that the null hypothesis is false, and the attributes
were statistically significantly correlated.
Results and discussion
Incubation at low pH
Incubation of 3,4-DHPEA-EDA and 3,4-DHPEA-EA at pH 2·0
led to the partial hydrolysis of both compounds and a corre-
sponding time-dependent increase in HT (Fig. 1). After 4 h
incubation, about 67 % of 3,4-DHPEA-EDA and 78 % of 3,4-
DHPEA-EA (Fig. 1(A) and (B)) remained. The present results
show that although some hydrolysis takes place releasing
free HT from both 3,4-DHPEA-EDA and 3,4-DHPEA-EA, a
large amount of both DHPEA-EDA and 3,4-DHPEA-EA (67
and 78 %, respectively, after 4 h) remains intact despite pro-
longed exposure to postprandial gastric conditions. This is
in agreement with previous studies, which suggest that both
compounds are also relatively stable at pH environments
akin to those in the small intestine with more than 90 % of
3,4-DHPEA-EDA and more than 65 % of 3,4-DHPEA-EA
remaining intact after a 48 h incubation at pH 7·4 (378C)(32).
These data suggest that both 3,4-DHPEA-EDA and 3,4-
DHPEA-EA may be relatively stable during transit through
the stomach and the small intestine in vivo. As a consequence,
both compounds are likely to arrive at relatively high
concentration in the small intestine where they may undergo
absorption and metabolism.
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Fig. 2. HPLC chromatogram with photodiode array detection (200–600 nm) of the cell culture apical (A, C) and basolateral (B, D) buffer from Caco-2 monolayers
after 2 h incubation with 3,4-dihydroxyphenylethanol-elenolic acid (3,4-DHPEA-EA) (A, B) and 3,4-dihydroxyphenylethanol-elenolic acid dialdehyde (3,4-DHPEA-
EDA) (C, D) at 100 mM. Detection was performed at 280 nm. HT, hydroxytyrosol; HVA, homovanillyl alcohol; EA, 3,4-DHPEA-EA; RT, retention time;
EDA, 3,4-DHPEA-EDA.
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Caco-2 cell model
Initial investigations into the ability of 3,4-DHPEA-EA and 3,4-
DHPEA-EDA to transfer across the small intestine were con-
ducted using the human Caco-2 cell model. Analysis of the
AP and BA medium demonstrated the enterocyte-mediated
transfer of both 3,4-DHPEA-EA and 3,4-DHPEA-EDA over a
2 h period (Fig. 2). After 2 h, the cis- and trans-isomers of
3,4-DHPEA-EA (retention time (RT): 44·6 and 46·1 min) were
detectable on the AP side (Fig. 2(A)), and a single isomer
was detected on the BA side of the cell monolayer
(Fig. 2(B)). Furthermore, its transfer to the BA side was
observed to increase with increasing exposure to the AP
side (Fig. 3(A), I–III). HT (RT: 8·2 min) was also detected on
both the AP and BA sides (Figs. 2 and 3), whereas HVA (RT:
15·8 min) was only detected on the AP side. Similarly,
3,4-DHPEA-EDA appeared to be transferred from the AP
side (Fig. 2(C)) to the BA side (Fig. 2(D)) in a concentration-
dependent manner (Fig. 3(B), I–III), where HT (RT: 8·2 min)
was also found. LC–MS of BA fluids confirmed the identity
of 3,4-DHPEA-EA and 3,4-DHPEA-EDA, indicating that they
appear to be capable of enterocytic transfer. LC–MS of the
AP medium following 3,4-DHPEA-EDA exposure (Fig. 2(C))
indicated the presence of HVA (RT: 15·8; m/z 153) and
another intense peak (RT: 25·8 min), which apparently had a
molecular peak of m/z ¼ 250 (other fragments: m/z ¼ 220
and 198). The peaks at 16·1 and 21·9 min on the BA side
were compounds related to normal enterocyte metabolism,
were present in controls and therefore we did not characterise
them.
These data appear to suggest that both 3,4-DHPEA-EA and
3,4-DHPEA-EDA are transferred across the small intestine.
However, while Caco-2 cell monolayers have been shown to
express a series of metabolic enzymes and efflux transpor-
ters(33,34), they are well known to overexpress some enzymes
and underexpress others. Although the Caco-2 cell model is
generally considered to be a suitable model for intestinal
CYP3A4-mediated first-pass metabolism, this is not the case
for (uridine 50-diphospho-glucuronosyl transferase)-mediated
glucuronidation(35,36), as they do not contain a full comp-
lement of intestinal drug-metabolising enzymes. However,
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correlated. , Hydroxytyrosol; , homovanillyl alcohol; , retention time (25·8 min); , secoiridoid.
Metabolism of olive oil secoiridoids 1611
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
they have been extensively used for assessing the small-
intestinal absorption and metabolism of polyphenols(24,37–39),
even though this cell system may not wholly reflect physio-
logical conditions in vivo. For example, several enzymes
involved in lipid and carbohydrate metabolism are overex-
pressed relative to the human intestinal epithelial cells(33),
whereas uridine 50-diphospho-glucuronosyl transferase(40),
catechol-O-methyl transferase, aldolase and retinal dehydro-
genase(33) are underexpressed. As such, the results obtained
from our cell studies may not fully reflect the degree to
which 3,4-DHPEA-EA and 3,4-DHPEA-EDA undergo enterocy-
tic metabolism in vivo. Furthermore, the reduced metabolic
capacity of these cells may result in an incomplete picture of
the actual pattern of 3,4-DHPEA-EA and 3,4-DHPEA-EDA
absorption and metabolism, most notably whether the parent
compounds are transferred intact in the presence of entero-
cytes with a normal metabolic capacity.
Perfused rat intestinal model
To help address this problem, we also carried out transfer
experiments in the isolated, perfused rat intestinal model,
which is known to possess full metabolic capacity for up to
120 min post-isolation(30,31). Using this model, we were able
to determine the comparative absorption of 3,4-DHPEA-EA
and DHPEA-EDA, and the extent to which they are conjugated
and metabolised during transfer across the jejunum and ileum.
HPLC analysis of the serosal fluid (equivalent to the portal
vein blood) following perfusion of the ileum with 3,4-
DHPEA-EA led to the detection of a number of peaks
(Fig. 4), which were characterised by diode array and MS.
These included HT (RT: 8·4 min; m/z 153), 3-O-methyl-HT
(HVA) (RT: 16·5min; m/z 153), HT glucuronide (RT: 6·8; m/z
329) and HVA glucuronide (RT: 11·5; m/z 343) (Fig. 4(A)).
In addition, there were two peaks at 44·6 and 45·5 min that
had similar, but not identical, spectral and RT characteristics
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Fig. 4. HPLC chromatogram with photodiode array detection (200–350 nm) of the absorbed fluid after 3,4-dihydroxyphenylethanol-elenolic acid (3,4-DHPEA-EA)
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to the cis- and trans-isomers of 3,4-DHPEA-EA and a further
four peaks at a RT between 38 and 43 min (Fig. 4(A)). MS anal-
ysis indicated that the four peaks at 38–43 min had a þ 2 mass
(m/z 555; negative ion mode) relative to that of 3,4-DHPEA-
EA glucuronide, indicating that they were glucuronides of
reduced forms of the cis- and trans-isomers of 3,4-DHPEA-
EA (Fig. 5). b-Glucuronidase treatment confirmed that these
were indeed glucuronides (Fig. 4(A)), and MS analysis of the
peaks at 44·6 and 45·5min, which appeared following enzyme
treatment (Fig. 4(B)), was shown to correspond to the reduced
cis- and trans-isomers of 3,4-DHPEA-EA (denoted as methyl 4-
(2-(3,4-dihydroxyphenethoxy)-2-oxoethyl)-3-(hydroxymethyl)-2-
methyl-3,4-dihydro-2H-pyran-5-carboxylate (3,4-DHPEA-EAH2);
molecular ion in negative mode of m/z ¼ 379 for both peaks).
We were unable to confirm the identity of the peaks at 44·6 and
45·5min (Fig. 4(A)) due to the small amounts transferred, although
these are likely to correspond either to 3,4-DHPEA-EA or its
reduced derivatives. Therefore, the quantification of these peaks
was denoted as EA/EAH2 and quantified as 3,4-DHPEA-EA
equivalents.
These results indicate that during transfer across the ileum,
3,4-DHPEA-EA undergoes both a two-electron reduction to
yield 3,4-DHPEA-EAH2 and mono-glucuronidation at two pos-
itions. Two sites of reduction are possible on 3,4-DHPEA-EA,
the alkenic double bond and the carbonyl group (Fig. 1(B)),
which may act as sites for the action of NADPH-dependent,
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Fig. 5. MS/MS (MS2) negative fragment ion spectrum of (A) m/z 555 (reduced 3,4-dihydroxyphenylethanol-elenolic acid (3,4-DHPEA-EA) glucuronides) and
(B) m/z 379 (reduced 3,4-DHPEA-EA) and proposed fragmentation. MW, molecular weight.
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aldo-keto reductase(41). Aldo-keto reductase enzymes are
widely distributed in mammals and include human aldose
reductase and human small intestine aldose reductase(42).
These enzymes are capable of catalysing the reduction of a
variety of carbonyl-containing compounds, and are respon-
sible for the reduction of retinal to retinol in the human
small intestine(42), as well as the reduction of various other
molecules, including carbohydrates, aliphatic and aromatic
aldehydes and steroids. We suggest that during transfer
across enterocytes, aldose reductase reduces the carbonyl
group of 3,4-DHPEA-EA, something that was consistent with
the MS fragmentation pattern of 3,4-DHPEA-EAH2 (Fig. 5).
Although we were unable to completely rule out the transfer
of 3,4-DHPEA-EA, it appears that its major bioavailable forms
in vivo are the glucuronides of reduced 3,4-DHPEA-EA
(methyl 4-(2-(3,4-dihydroxyphenyl)-ethoxycarbonylmethyl)-
3-hydroxymethyl-2-methyl-3,4-dihydro-2H-pyran-5-carboxylate).
Presumably, we did not observe these in the cell model due to
the underexpression of these enzymes.
Similar observations were made following perfusion of the
ileum with 3,4-DHPEA-EDA (Fig. 6). HT (RT: 8·0 min), HVA
(RT: 15·8 min) and the respective glucuronides of these com-
pounds (RT: 7·6 and 11·8 min) were observed in the serosal
fluid (Fig. 6(A)). In addition, there were two peaks at 30·7
and 32·1 min and a further peak at 34·4 min with a similar,
but not identical, spectral and RT characteristics to 3,4-
DHPEA-EDA. Full scan analysis of the serosal fluid collected
after 3,4-DHPEA-EDA perfusion did not indicate the presence
of the [M 2 H]2 ion corresponding to 3,4-DHPEA-EDA (m/z
319) or to its reduced form (3,4-DHPEA-EDAH2 (2-(3,4-dihy-
droxyphenyl)ethyl (4E)-4-formyl-3-(2-hydroxyethyl)hex-4-
enoate), m/z 321). However, two glucuronides of the reduced
form of 3,4-DHPEA-EDA were detected (RT: 30·7 and
32·1 min, m/z 497 in negative ion mode), which disappeared
following b-glucuronidase treatment (Fig. 6(B)) with a sub-
sequent increase in a peak at 34·4 min corresponding to a
reduced form of 3,4-DHPEA-EDA (m/z 321 in negative ion
mode). Again, the fragmentation of the molecular ion corre-
sponding to 3,4-DHPEA-EDAH2 (m/z 321) indicated that a
reduction of one of the two carbonyl groups present on 3,4-
DHPEA-EDA had occurred during transfer across the ileum
(Fig. 7), along with glucuronidation. We were unable to
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Fig. 6. HPLC chromatogram with photodiode array detection (200–350 nm) of the absorbed fluid after 3,4-dihydroxyphenylethanol-elenolic acid dialdehyde
(3,4-DHPEA-EDA) perfusion through the isolated rat ileum. (A) Absorbed fluid and (B) absorbed fluid treated with b-glucuronidase. Detection was performed at
280 nm. HT, hydroxytyrosol; HVA, homovanillyl alcohol; EDA, 3,4-dihydroxyphenylethanol-elenolic acid; EDAH2, reduced 3,4-DHPEA-EDA.
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confirm which of the carbonyl functional groups had under-
gone reduction since reduction at either site would yield simi-
lar fragmentation patterns.
Perfusion of the jejunum with both 3,4-DHPEA-EDA and
3,4-DHPEA-EA also resulted in their extensive reduction and
glucuronidation in a similar manner to that seen in the
ileum. However, both 3,4-DHPEA-EDA and 3,4-DHPEA-EA
metabolites were transferred to a greater extent in the jejunum
compared with the ileum (Fig. 8(A)). This difference was
especially apparent for 3,4-DHPEA-EA where the concen-
tration of 3,4-DHPEA-EAH2 glucuronide was four times
higher in the jejunum serosal fluid than in the ileum serosal
fluid. Furthermore, transfer of compounds and appearance
of metabolites reached a maximum at about 60 min (Fig. 8(A)
and (B)), reflecting the initial slow uptake of components into
cells and followed by their enzymatic reduction and glucuro-
nidation. The small reduction in compound/metabolite con-
centration in the jejunum at 90 min is likely to reflect a loss
of viability in the intestinal segment at this late stage. There
were also notable differences in the patterns of metabolism
occurring between the jejunum and ileum, with ileum appear-
ing to display a lower reductase and glucuronidase activity
compared with the jejunum (Fig. 8). This is in agreement
with previous studies indicating that the ileum expresses a
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much lower glucuronidase activity towards transferred flavo-
noids relative to the jejunum(31). Nevertheless, when consider-
ing the small intestine as a whole, glucuronides of 3,4-DHPEA-
EAH2 and 3,4-DHPEA-EDAH2 represent the major small-intes-
tinal metabolites entering the portal blood.
Conclusion
Previous human intervention studies have failed to clearly
identify 3,4-DHPEA-EA in either the plasma or urine following
olive oil ingestion(19–21), while 3,4-DHPEA-EDA has only been
measured in the plasma of one subject (out of five) in a recent
study performed by Suarez et al.(43). The inability to character-
ise and quantify these components may partially relate to a
lack of commercially available secoiridoid standards and a
focus on the detection of HT and tyrosol in biological samples.
However, our data suggest that the inability to detect 3,4-
DHPEA-EDA and 3,4-DHPEA-EA (or their glucuronides) in
biological fluids is more likely to be due to the fact that they
are not absorbed in the parental form, and thus they are not
major bioavailable forms in vivo. Indeed, we show for the
first time that the major small-intestinal metabolites of these
secoiridoids are glucuronide conjugates of 3,4-DHPEA-EDA
and 3,4-DHPEA-EA that have undergone reduction (most
probably enzymatic) during enterocytic transfer. As such, pre-
vious studies are unlikely to have captured the full extent of
absorption and metabolism of these olive oil components, as
they would have failed to take account of these reduced
forms. Therefore, it seems reasonable that previous human
studies aimed at investigating the pharmacokinetics of such
olive oil secoiridoids may have underestimated the full
extent of their absorption. Future studies should take account
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Fig. 8. (A) Cumulative absorption of olive oil polyphenols and their metabolites over 80 min through the isolated rat jejunum and ileum after perfusion with
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of the novel metabolites identified in the present study, and
those resulting from intestinal micobiota-induced metab-
olism(23), when investigating biological fluids. Furthermore,
such metabolites should be investigated for their cellular and
molecular effects in in vitro models, as such metabolites
may possess biological activities that underpin the benefits
of olive oil consumption in humans.
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